Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionJohn J.V. McMurray, Anna-Maria Langkilde, Vijay Chopra et al.|New England Journal of Medicine|2019Cited by 6.8k
Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) TrialMarc A. Pfeffer, Bertram Pitt, Brian Claggett et al.|Circulation|2014Cited by 1k
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionScott D. Solomon, Marc A. Pfeffer, Brian Claggett et al.|European Heart Journal|2015Cited by 524
Dapagliflozin and New York Heart Association functional class in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trialJohn W. Ostrominski, Scott D. Solomon, Muthiah Vaduganathan et al.|European Journal of Heart Failure|2022Cited by 32
Mechanisms of diabetic cardiomyopathy: Focus on inflammationMyriam Bellemare, Nadia Bouabdallaoui, Liane Bourcier et al.|Diabetes Obesity and Metabolism|2025Cited by 32